PAD Formulary : Surrey Heartlands
PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Bevacizumab - Uveitis

PAD Profile : Bevacizumab - Uveitis

Brand Names Include :
Avastin

Traffic Light Status

Status 1 of 1.

Status :
Red
Important
Formulations :
  • Intravitreal injection
Important Information :
2nd line option where intravitreal dexamethasone is contraindicated
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
NFD1
Un
ICB
BlueTeq
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Evidence Review
Bevacizumab for Uveitis - Evidence Review - October 2013

Committee Recommendations

Date
Committee Name
Narrative
30 October 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
PCN supported the use of bevacizumab as a second line treatment option for patients with non-infectious sight threatening or sight-losing intermediate or posterior uveitis who are unable to receive intravitreal dexamethasone (Ozurdex) due to a contraindication.

Associated BNF Codes

11. Eye
11.08.02. Ocular diagnostic & peri-operative prepn & photodynamic tt
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
 Learn More